Background/Aims: H. pylon eradication has been recommended for dyspeptic patients in high prevalance regions. Triple therapies are still prescribed mostly because culture and antibiotic susceptibility tests aren-t widely available in the world. Dual therapy with high-dose proton pump inhibitors reported to have higher eradication rates. Our objective was to determine eradication success and cost-effectivity of dual therapy in dyspeptic patients. Methodology: Patients were treated orally with either dual (n:74,omeprazole 20mg q.i.d and amoxicillin 1g b.i.d) or triple therapy (n:116,omeprazole 20mg b.i.d and amoxicillin 1g b.i.d and clarithromycin 500mg b.i.d) for 14 days. HpSA was requested 3 months later. The results were evaluated statistically, p values <0,05 were considered significant. Results: Patients (n:190) were included the study((80 female,110 male, mean age: 35.6 11yearr). Alcohol/smoking, endoscopic findings and H. pylon rates with pathological examinations were not significantly different between groups whereas there was significant difference in HpFast tests(p<0.01). Whe examined with HpSA tests 3 months after the treatment eradication rate was 81.1% in the dual therapy group versus 63.8% in the triple therapy group (p:0.011) Dual therapy was economic than triple therapy (144USDvs.107USD,p<0.001). Conclusions: Dual therapy seems more successful cost-effective and is less risky in terms of side effects compared to standard triple therapy in patients with dyspepsia.